Conatumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.

**Synonyms:** - AMG 655 - Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655 - CONATUMUMAB - Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen)) - Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer